V A C M Koeken1, A J Verrall2, M G Netea3, P C Hill4, R van Crevel5. 1. Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, the Netherlands. 2. Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand. 3. Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, the Netherlands; Department for Genomics & Immunoregulation, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany. 4. Centre for International Health, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand. 5. Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, the Netherlands. Electronic address: reinout.vancrevel@radboudumc.nl.
Abstract
BACKGROUND: Some individuals, even when heavily exposed to an infectious tuberculosis patient, develop neither active nor latent tuberculosis infection (LTBI). This 'early clearance' of Mycobacterium tuberculosis is associated with a history of bacillus Calmette-Guérin (BCG) vaccination. As BCG vaccination can boost innate immune responses through a process termed 'trained immunity', we hypothesize that BCG-induced trained innate immunity contributes to early clearance of M. tuberculosis. OBJECTIVES: We describe the epidemiological evidence and biological concepts of early clearance and trained immunity, and the possible relation between these two processes through BCG vaccination. SOURCES: Relevant data from published reports up to November 2018 were examined in the conduct of this review. CONTENT: Several observational studies and one recent randomized trial support the concept that boosting innate immunity contributes to protection against M. tuberculosis infection, with BCG vaccination providing approximately 50% protection. The molecular mechanisms mediating early clearance remain largely unknown, but we propose that trained immunity, characterized by epigenetic and metabolic reprogramming of innate immune cells such as monocytes or macrophages, is at least partially responsible for eliminating the mycobacteria and inducing early clearance. IMPLICATIONS: Future studies should examine if BCG revaccination increases early clearance of M. tuberculosis through induction of trained immunity. Epigenetic or metabolic modulation may further boost BCG-induced trained innate immunity to promote tuberculosis prevention. New tuberculosis vaccine candidates should also be examined for their capacity to improve protection against M. tuberculosis infection and induce trained immunity.
BACKGROUND: Some individuals, even when heavily exposed to an infectious tuberculosispatient, develop neither active nor latent tuberculosis infection (LTBI). This 'early clearance' of Mycobacterium tuberculosis is associated with a history of bacillus Calmette-Guérin (BCG) vaccination. As BCG vaccination can boost innate immune responses through a process termed 'trained immunity', we hypothesize that BCG-induced trained innate immunity contributes to early clearance of M. tuberculosis. OBJECTIVES: We describe the epidemiological evidence and biological concepts of early clearance and trained immunity, and the possible relation between these two processes through BCG vaccination. SOURCES: Relevant data from published reports up to November 2018 were examined in the conduct of this review. CONTENT: Several observational studies and one recent randomized trial support the concept that boosting innate immunity contributes to protection against M. tuberculosis infection, with BCG vaccination providing approximately 50% protection. The molecular mechanisms mediating early clearance remain largely unknown, but we propose that trained immunity, characterized by epigenetic and metabolic reprogramming of innate immune cells such as monocytes or macrophages, is at least partially responsible for eliminating the mycobacteria and inducing early clearance. IMPLICATIONS: Future studies should examine if BCG revaccination increases early clearance of M. tuberculosis through induction of trained immunity. Epigenetic or metabolic modulation may further boost BCG-induced trained innate immunity to promote tuberculosis prevention. New tuberculosis vaccine candidates should also be examined for their capacity to improve protection against M. tuberculosis infection and induce trained immunity.
Authors: Alisha M Smith; Nathan Harper; Justin A Meunier; Anne P Branum; Fabio Jimenez; Lavanya Pandranki; Andrew Carrillo; Charles S Dela Cruz; Marcos I Restrepo; Diego J Maselli; Cynthia G Rather; Anna H Heisser; Daniel A Ramirez; Weijing He; Robert A Clark; Charles P Andrews; Scott E Evans; Jacqueline A Pugh; Nu Zhang; Grace C Lee; Alvaro G Moreira; Leopoldo N Segal; Robert M Ramirez; Robert L Jacobs; Muthu Saravanan Manoharan; Jason F Okulicz; Sunil K Ahuja Journal: J Allergy Clin Immunol Date: 2021-01-23 Impact factor: 14.290
Authors: Bridget Freyne; Nicole L Messina; Susan Donath; Susie Germano; Rhian Bonnici; Kaya Gardiner; Dan Casalaz; Roy M Robins-Browne; Mihai G Netea; Katie L Flanagan; Toby Kollmann; Nigel Curtis Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Simone J C F M Moorlag; Nargis Khan; Boris Novakovic; Eva Kaufmann; Trees Jansen; Reinout van Crevel; Maziar Divangahi; Mihai G Netea Journal: Cell Rep Date: 2020-05-19 Impact factor: 9.423
Authors: Donal J Cox; Amy M Coleman; Karl M Gogan; James J Phelan; Cilian Ó Maoldomhnaigh; Pádraic J Dunne; Sharee A Basdeo; Joseph Keane Journal: Front Immunol Date: 2020-07-23 Impact factor: 7.561
Authors: Valerie A C M Koeken; Eva S van der Pasch; Guus P Leijte; Vera P Mourits; L Charlotte J de Bree; Simone J C F M Moorlag; Isadore Budnick; Nina Idh; Maria Lerm; Matthijs Kox; Arjan van Laarhoven; Mihai G Netea; Reinout van Crevel Journal: Cytokine Date: 2020-06-10 Impact factor: 3.861